Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy.
Nasdaq

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

– Donidalorsen is currently under review with the U.S. FDA as a potential first-in-class prophylactic treatment for HAE; PDUFA date August 21 – “In this study, we saw that patients were able to switch ...
Medicine Buffalo

Study reveals ‘switch-like’ behavior for hundreds of genes with links to human disease

Gene expression, where cells use the genetic information encoded in DNA to produce proteins, has been thought of as a dimmer light. How much a particular gene gets expressed continually rises and ...